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Abstract 
Adoptive transfer of Chimeric Antigen Receptor transduced T cells is a promising strategy 
for cancer immunotherapy. The CD38 molecule, with its high expression on Multiple 
Myeloma cells, appears a suitable target for antibody therapy. Prompted by this, we used 
three different CD38 antibody sequences to generate second generation retroviral CD38- 
Chimeric Antigen Receptor constructs; transduced T cells of healthy donors and Multiple 
Myeloma patients and evaluated their preclinical efficacy and safety. Irrespective of the 
donor and antibody sequence, CD38-Chimeric Antigen Receptor transduced T cells 
proliferated, produced inflammatory cytokines and effectively lysed malignant cell lines and 
primary malignant cells from acute myeloid leukemia and multi-drug resistant Multiple 
Myeloma patients in a cell-dose, and CD38-dependent manner, despite becoming CD38 
negative during culture. CD38-Chimeric Antigen Receptor transduced T cells also displayed 
significant anti-tumor effects in a xenotransplant model, in which Multiple Myeloma tumors 
were grown in a human bone marrow-like microenvironment. CD38-Chimeric Antigen 
Receptor transduced T cells, also appeared to lyse the CD38+ fractions CD34+ 
hematopoietic progenitor cells, monocytes, natural killer cells, and to a lesser extent T and 
B cells but, did not inhibit the outgrowth progenitor cells into various myeloid lineages, and 
were furthermore effectively controllable with a caspase-9-based suicide gene. These 
results signify the potential importance of CD38-Chimeric Antigen Receptor transduced T 
cells as therapeutic tools for CD38+ malignancies and warrant further diminishing their 
undesired effects using appropriate strategies.  
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Introduction 
Multiple myeloma (MM), the malignant disorder of antibody producing clonal plasma cells is 
the second most common hematologic neoplasia worldwide.1 Despite four decades of drug 
innovation, MM remains incurable with chemotherapy. Furthermore, the prognosis of MM 
patients, who become refractory to recently developed novel agents, is very poor.2 On the 
other hand, clinical and experimental data collected over the past decades suggest the 
possibility to successfully treat MM through (cellular) immunotherapy.3,4 The curative 
potential of cellular immunotherapy in MM is illustrated by the induction of long-term 
sustained remissions after allogeneic stem cell transplantation (SCT) or donor lymphocyte 
infusions (DLI) in a subset of patients.5,6 A highly appealing and more specific 
immunotherapy strategy for cancer is the adoptive transfer of cytotoxic T cells (CTLs) that 
are genetically engineered to express Chimeric Antigen Receptors (CAR).7,8 A CAR is an 
artificial hybrid receptor, in which the antigen recognizing domain of a tumor-reactive 
monoclonal antibody is fused with T-cell signaling domains. Upon retro- or lentiviral 
transduction of CTLs, CARs expressed on the cell surface redirect the CTLs toward the 
original target of the antibody in a non-HLA restricted manner7,8, providing the possibility to 
apply the therapy regardless of the HLA type of the patient. Currently the most successful 
CAR-approaches are based on targeting the CD19 molecule, which is broadly expressed in 
several B cell malignancies but not on malignant plasma cells of MM patients. Among a few 
potential CAR candidates for MM9, the CD38 molecule, with its high and uniform expression 
on malignant plasma cells, has long been suggested a suitable target for antibody therapy 
of MM. The utility of CD38 as a suitable target has indeed been supported by the results of 
recently initiated clinical trials in which MM patients were safely and effectively treated with 
the CD38-specific human monoclonal antibody daratumumab10. 
Encouraged by these clinical results, we now started to explore the feasibility of 
development of a CART cell therapy based on targeting the CD38 molecule. Using variable 
heavy and light chain sequences of three different human CD38 antibodies, we generated 
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three different CD38-CARs. We transduced T cells from healthy individuals and MM 
patients with CD38-CARs and evaluated them for essential functions such as antigen-
specific proliferation and cytokine production, for in vitro and in vivo anti-tumor efficacy and 
for potential undesired effects such as targeting normal CD38+ cell fractions in the 
peripheral blood and bone marrow. We also evaluated the feasibility of controlling CD38-
CART cells by introduction of a caspase-9 based suicide gene.   
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Methods 
Bone marrow Mononuclear cells (BM-MNC) from MM and AML patients   
Bone marrow mononuclear cells containing 5-20% malignant plasma cells or ~50% AML 
blasts were isolated from bone marrow aspirates of MM/AML patients through Ficoll-Paque 
density centrifugation and cryopreserved in liquid nitrogen until use. All bone marrow and 
blood sampling from the patients was performed after informed consent and approved by 
the institutional medical ethical committee.   
PBMC from healthy individuals   
PBMCs were isolated from Buffy coats of healthy blood-bank donors by Ficoll-Paque 
density centrifugation after informed consent and approval by the institutional medical 
ethical committee.  
Retroviral constructs   
The sequences of three different human CD38 antibodies, which are distinct from, but 
display similar affinities to the recently documented daratumumab10 (Table S1) were kindly 
provided by Genmab. Cloning methods are described in supplementary methods.  
Retroviral CAR Transduction into T cells 
Transduction methods are described in supplementary methods.  
Flow cytometry-based cell lysis assays  
To detect the lysis of various cell subsets by CART cells in whole BMNC or in PBMC, serial 
dilutions of CART cells were incubated with CFSE labeled BMMNC or PBMC for 24 hours. 
The cells were then harvested, stained for different CD markers and topro3 or LIVE/DEAD® 
Fixable Near-IR (Life Technologies L10119) and were quantitatively analyzed through 
volume-equalized measurements using a FACS Canto flow cytometer. For each cell subset 
identified with a CD marker, CFSE+, viable+/Topro3- cells were counted as surviving target 
cells. Percentage cell lysis in a treated sample was calculated as follows and only if the 
analyzed target cell population contained >500 viable cells in the untreated samples. % lysis 
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cells = 1 − (absolute number of surviving cells in treated wells / absolute number of 
surviving cells in untreated wells) × 100%. 
BLI-based cell lysis assays   
To determine the lysis of Luc-GFP-transduced human malignant cell lines by CD38-CART 
cells, serial dilutions of mock or CD38-CART cells were co-incubated with the malignant cell 
lines. The luciferase signal produced by surviving malignant cells was determined after 16-
24 hours with a luminometer SpectraMax, Molecular Devices within 15 minutes after the 
addition of 125 μg/mL beetle luciferin (Promega).11 The percent lysis was then calculated as 
in flow-based cytotoxicity assay above.  
Experimental animals 
RAG2-/-γc-/- mice used in this study were originally obtained from the Amsterdam Medical 
Center (AMC, Amsterdam, the Netherlands). The mice were bred and maintained in filter 
top cages under specified pathogen-free conditions at the Central Animal Facility (GDL, 
Utrecht University, Utrecht, the Netherlands) and received sterile water and radiation-
sterilized food pellets ad libitum. 
In vivo efficacy of CD38-CART cells against MM tumors growing in a humanized 
microenvironment. 
To create a human bone marrow-like environment in mice, hybrid scaffolds were coated in 
vitro with human mesenchymal stromal cells. After a week of in vitro culture, humanized 
scaffolds were seeded with CD38+ UM9 cells and implanted subcutaneously into the mice, 
as described previously,11,12 and described in supplementary methods. 
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Results 
Generation of CD38-CART cells 
We used the variable heavy and light chain sequences of three different CD38 antibodies 
with CD38 binding affinities comparable to daratumumab (Table S1), which is now being 
tested in clinical trials. T cells from healthy PBMC were transduced with the different CD38-
CAR genes or with the empty vector (mock) separately. After selection of transduced cells 
to high purity by neomycin treatment, the surface expression of CARs was determined by 
incubating the T cells with biotinylated bacterial protein L, which specifically binds to the 
variable region of kappa light chains of antibodies.13 Indirect staining with PE-conjugated 
streptavidin revealed the expression of all three CARs on >95% of the T cells, whereas T 
cells transduced with an empty vector (mock-transduced T cells) displayed only background 
staining (Fig. 1B left panel). The CAR-transduced cells contained variable levels of both 
CD4+ and CD8+ cells (Fig. 1B; right panel).  
CD38-dependent proliferation and cytokine secretion of CD38-CART cells. 
To analyze the proliferative and functional properties, the neomycin-selected, highly purified 
CD38-CART cells were expanded using irradiated feeder cells in the presence of PHA and 
IL-2. While the mock T cells initially expanded better than the CD38-CART cells (Fig. 1C; 
left panel), the growth disadvantage of CD38-CART cells disappeared in the second 
expansion round (Fig. 1C; right panel), indicating that transduction of CD38-CAR construct 
did not affect the proliferative capacity of T cells. We then tested whether CD38-CART cells 
can be activated by CD38-triggering. To this end, we co-cultured mock- and CD38-CAR-
transduced T cells with irradiated CD38+ MM cell line UM9 and used the CD38- MM cell line 
U266 as a control (Fig. 1D; left panel). CD38-CART cells, but not mock T cells, specifically 
proliferated and produced IFN-γ, TNF-α and IL-2 (Fig.1D; right panel), but not IL-4, -5 and -
10 (data not shown) upon stimulation with UM9 cells. These results indicated that CD38 
CART cells had no defects in cytokine production but displayed a typical Th1-like cytokine 
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response upon target recognition. Furthermore, the CD38- cell line U266 was unable to 
stimulate CD38-CART cells, demonstrating the proper antigen-specific function of CD38-
CART cells.  
 CD38-dependent lysis of MM cell lines by CD38-CART cells  
To determine the CD38-dependent lysis of malignant cells by CD38-CART cells, we first 
used luciferase-transduced MM cell lines with variable CD38 expression levels in BLI-based 
cytotoxicity assays.11,14 As expected, there was no CD38-CAR-specific lysis of the CD38- 
U266 cell line (Fig. 2A). In contrast, all three CD38-CART cells, but not mock-T cells, 
effectively lysed CD38+ MM cell line UM9 in a cell-dose dependent manner (Fig. 2B), 
showing the feasibility of generating effective CART cells with any of the CD38 antibody 
sequences we used. Since there was no functional difference between the three different 
CD38-CARs (028, 056, 026), we continued our investigation with one type of CD38-CART 
cell (CAR056). Flow cytometry and BLI-based cytotoxicity assays, executed using other 
malignant cell lines expressing various levels of CD38 (Supplementary Fig.S1) as target 
cells revealed a good correlation between the CD38 expression and CD38-CART cell-
mediated lysis (Fig. 2C). Though one AML cell line, the Burkitt lymphoma-derived cell line 
Daudi as well as normal T cells appeared less sensitive to CD38-CART cell mediated lysis 
as compared to MM cell lines with similar levels of CD38 expression (Fig. 2C). 
Lysis of primary MM and AML cells by CD38-CART cells.  
To test the efficacy of CD38-CART cells against primary MM and AML cells, we used a 
previously described flow cytometry-based ex vivo cytotoxicity assay, in which the lysis of 
malignant cells is tested, directly in the BM-MNCs without isolating them from other cells.15 
As depicted in Figure 3A, primary CD138+CD38+ MM cells of three different MM patients, 
who were refractory to treatment with lenalidomide, and bortezomib (left panel), were 
effectively lysed by CD38-CART cells, but not by mock-transduced T cells. Similarly in the 
BM-MNCs of two Acute Myeloid Leukemia (AML) patients malignant cells, which were 
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identified as CD13+ CD45+ cells and expressed either low/intermediate (patient 1) or high 
CD38 (patient 2) were effectively lysed by CD38-CART cells (Fig 3A). Finally, CD38-CART 
cells that were generated (Fig 3B) from a MM patient were effective towards autologous 
malignant MM cells in BM-MNCs indicating the feasibility of generating effective 
CD38CART cells also from MM patients. 
Fully-functional CD38 CART cells are negative for CD38 
While CD38-CART cells had no apparent functional deficiencies, a phenotyping assay 
revealed that they, despite a mixed effector/central memory phenotype, lost the expression 
of CD38 (Fig. 4A). Interestingly, when we co-cultured CD38-CART cells with an autologous 
CD19 CART cell population, these CD19CART cells also became largely negative for CD38 
expression but fully maintained their capacities to proliferate, secrete cytokines and kill the 
relevant target cells in a CD19 dependent fashion (supplementary Figure S2), indicating 
that the loss of CD38 was not associated with detectable T cell dysfunction. Nonetheless, 
since CD38 molecule could also play a role in migration, we also evaluated whether CD38 
negative CD38-CART cells would properly migrate through endothelial layers in a transwell 
migration assay (fig 4B). These assays revealed no differences between the mock-
transduced, CD38-positive and CD38-CAR-transduced CD38-negative T cells, ruling out an 
apparent migratory dysfunction of CD38-CART cells.  
In vivo efficacy of CD38-CART cells against MM tumors growing in a humanized 
microenvironment.  
To substantiate the in vitro results, we questioned whether the CD38 negative CART cells 
could mediate in vivo anti-MM effects after systemic injection in our recently developed 
model in Rag2-/-γc-/- mice, in which a humanized BM like-niche for MM cells are generated 
by s.c. implantation of ceramic scaffolds coated with human bone marrow stromal cells (hu-
BMSCs)11,12 (Fig4). Thus, we implanted huBMSC-coated scaffolds seeded with luciferase-
transduced UM9 MM cells in the back of the mice (6 scaffolds per mouse). Upon detection 
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of luciferase signal by BLI, we treated the mice by i.v. injections of CD38-CART cells using 
a previously established treatment scheme.16 Mock-transduced T cells were used as 
controls. As illustrated in Figure 4B, in the control group treated with mock T cells, tumors 
showed a fast progression. Although not curative, treatment of the tumor-bearing mice with 
CD38-CART cells induced a significant anti-tumor effect (Fig. 4B,C) underscoring the 
potential of CD38-CART cells to properly infiltrate and lyse MM tumors growing in their 
natural, protective niche. Post mortem analyses revealed that the remaining CD138+ tumors 
were still positive for CD38 (Fig. 4D), thus ruling out tumor escape due to “antigen loss” 
variants. 
Impact of CD38-CART cells on CD38+ normal hematopoietic cells and hematopoietic 
progenitor cells. 
Besides the high expression levels in MM cells, the CD38 molecule is expressed at 
intermediate levels on a subset of hematopoietic progenitor cells17 and on a fraction of 
normal hematopoietic cells including activated T cells, NK cells, B cells and monocytes. We 
therefore evaluated the possible negative impact of CAR-T cells on these cell subsets by 
co-incubating unsorted BM-MNCs with CD38-CART cells. CD38-CART cells appeared to 
eliminate the CD38+ fractions of mature T, B, NK and monocyte cell subsets (Fig. 5A) and 
the CD38+ fraction of CD34+ cells (Fig. 5B) in a 4 hour assay. The lysis of CD34+CD38+ 
cells had however no influence on the development of colony-forming unit-monocytes 
(CFU-M), and CFU-granulocytes (CFU-G) in a 14-day hematopoietic precursor cell (HPC) 
colony forming assay18,19 (Fig. 5C and D). 
Specific elimination of CD38-CART cells using a suicide gene (iCasp9) 
Although CD38-CART cells did not lyse the CD38 negative fractions of mature 
hematopoietic cells and did not inhibit the outgrowth of these cell populations, still a 
cautious approach toward the clinical application is required. Therefore, as a first step 
towards a more safe application of CD38-CART cells, we tested the possibility to control 
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them with a suicide gene based on the inducible caspase-9 (iCasp9) gene that is activated 
with a small dimerizer molecule AP20187 (B/B).20 Thus, we inserted an iCasp9 vector 
containing a GFP marker gene into the CD38-CART cells by retroviral transduction. Around 
50% of the CD38-CART cells were transduced as detected by GFP expression (figure 6A, 
upper panel) When tested without sorting the iCasp9 transduced (GFP+) cells, all iCasp9 
transduced, GFP+ but none of the iCasp9 non-transduced, GFP-CD38-CART cells were 
eliminated upon incubation with the dimerizer AP20187 (Fig. 6A lower panel). As expected, 
the dimerizer treatment also resulted in a proportional decrease in the lysis of the MM cell 
line UM9. (Fig. 6B). There was still a remaining lysis due to the surviving iCasp9 negative 
CD38-CART cells, indicating that the triggering of suicide gene induced no bystander 
damage to the cells in the close vicinity. When tested after sorting of GFP+ cells (Fig 6C 
and 6D), almost all GFP+ cells died after treatment with the dimerizer (Fig. 6C) and there 
was no CD38 specific lysis left (Fig 6D), confirming the results obtained by previous 
studies20,21, and suggesting the possibility to control CD38-CART cells using the iCasp9 
suicide gene without undesired consequences.  
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Discussion 
While cellular immunotherapy of hematological malignancies has been applied for many 
decades in the most non-specific form as allo-SCT or DLI, it has recently entered a more 
specific level of innovation with several encouraging strategies, including vaccination with 
antigen-loaded dendritic cells or adoptive immunotherapy with TCR-gene transferred T 
cells, tumor infiltrating T cells and more recently with CTLs endowed with tumor-reactive 
CARs. Among these strategies, CAR-based therapies are perhaps the most appealing, as 
CART cells recognize their target antigens in an MHC-independent manner. Set out to 
develop a CAR-based strategy for MM, we have been encouraged by the highly promising 
clinical results of the therapy with daratumumab, which targets CD38, a type II 
transmembrane glycoprotein, expressed with high and uniform levels in most, if not all, MM 
cells in all stages of the disease10. Recently daratumumab has been applied to several 
patients at moderate to high doses and for prolonged periods with little or no toxicity. This, 
despite the fact that CD38 molecule is also expressed, albeit at lower levels, on a fraction of 
hematopoietic cells, cerebellar purkinje cells, liver and lung smooth muscle cells, and 
insulin-secreting β cells of pancreas.17 Our study was therefore designed to test the 
feasibility, potential efficacy and pitfalls of a CD38-based CART cell approach for MM. To 
investigate the feasibility of generating CD38-CARs, we started the investigation using three 
distinct human CD38 antibodies, which displayed similar binding affinities to CD38 as 
daratumumab (Supplementary Table S1). Based on successful usage of 4-1BB-containing 
CARs in recent studies22–24 we have constructed CARs containing 4-1BB (CD137) co-
stimulatory and CD3ζ activating domains. Our results demonstrate the successful 
generation of CD38-CARs and CD38-CART cells regardless of the antibody sequences. T 
cells transduced with these CD38-CARs are highly proliferative, produce inflammatory Th1 
like cytokines and, most importantly, are effective in killing malignant cells and normal 
hematopoietic cells in a CD38-dependent fashion, with some subtle differences between 
cell lines or hematopoietic cell types.  
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More importantly, CD38-CART cells appeared capable of eliminating primary CD38+ MM 
cells of patients who became resistant to various chemotherapies. This suggests that 
CD38-CAR therapy could be a viable option for patients with little or no further 
chemotherapy options. These in vitro data were substantiated by the results obtained in our 
in vivo model. Although we did not observe the complete eradication of MM cells in our in 
vivo assays, we need to note that, since our CD38-CART cells appeared to lose their CD38 
expression upon culture, we primarily designed our in vivo assays to determine the anti-
tumor efficacy of these CD38 negative, but long-term cultured CD38-CART cells. This may 
have negatively influenced the anti-tumor efficacy, since it is known that long-term cultured 
T cells rapidly lose their in vivo persistence capacities.25,26 In addition, and perhaps even 
more important, in our model, unlike all previously reported CAR studies, the human MM 
tumors are grown to larger masses in a fully humanized BM microenvironment. The MM 
microenvironment is known to provide essential signals for survival, growth and more 
importantly immune resistance of MM cells.11,12,27,28 Since our model includes some of the 
microenvironment related aspects, our results suggest that it the efficacy of CART cell 
treatment could be improved if the therapy would be combined with immune checkpoint 
inhibitors and or with survivin and/or MCL-1 inhibitors which are effective modifiers of cell 
adhesion mediated immune resistance (CAM-IR) induced by tumor microenvironment.11 
Unlike a number of earlier reports, which mainly focused on the anti-tumor efficacy of CD38-
CART cells,29–31 we devoted a considerable part of our investigation on identifying the 
potential drawbacks and risks of the CD38-CART cell therapy. Although CD38-CART cells 
eliminated the CD38+ fractions of immune cell subsets as well as the CD38+ fraction of 
hematopoietic progenitor cells, we observed no inhibition of the outgrowth of hematopoietic 
lineages from CD34+CD38- progenitor cells. Furthermore, CD38-CART cells did not induce 
complete depletion of mature hematopoietic cells in the periphery. The CD38 negative 
fractions of important immune cells, such as B and T cells, were unaffected as well. These 
results suggest that the therapy will spare sufficient numbers of T and B cells to maintain 
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their functions. However, since CD38 is a well-known T cell activation molecule, and has 
also been implicated in chemotaxis,32 T cell development33, dendritic cell trafficking and 
humoral immune responses34, it would be relevant to answer the question whether an intact 
immune response would be possible in the absence of CD38. A partial answer to this issue 
came from the analyses of CD38-CART cells: we remarkably discovered that the CD38-
CART cells, regardless of which scFv was used, became completely devoid of CD38 
expression on their surface in various independently generated batches of cells. The loss of 
CD38 was thus unlikely to be caused by a genetic defect, but was most probably due to the 
“self lysis” of the CD38+ fractions, which was also described in another CD38-CAR study29. 
Our CD38 negative CD38-CART cells, however, had no growth disadvantage, displayed 
highly activated status, CD38-dependent proliferation, cytokine production, cytotoxic 
activities and showed no other detectable functional aberrancies. This was also the case for 
CD19CART cells which became CD38 negative after co-culture with CD38-CART cells 
(Figure S2). Furthermore CD38-CART cells did not show any defects in a transmigration 
assays and they also mediated significant anti-MM effects in vivo, thus indicating their 
capacity to properly migrate and infiltrate into the MM niches and to kill them. Thus, it 
seems likely that i) not all activated T cells have to be CD38 positive and ii) CD38 
expression is not essential for T cells to fulfill their functions. This conclusion is also 
supported by the fact that there is yet no evidence, even in CD38 KO mice,32 that CD38-
deficient effector T cells are defective in function.  
On the other hand, the relative broad expression of the target antigen of CD38-CART cells 
increases the risk of the so called “cytokine release syndrome (CRS)” due to massive 
activation of CAR-T cells, as have been observed in the previous trials with ERBB2- and 
CD19-CART cells.35–37 Although the IL-6R antagonist tocilizumab appears to successfully 
reduce CRS38 it would still be desirable to minimize the occurrence of such severe side 
effects. Furthermore, since we cannot rule out toxicities occurring die to the possible attack 
of non-hematopoietic CD38+ cells, development of an optimal CD38-CART cell therapy 
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would require the improvement of the target-specificity as well as the in vivo control on 
CD38-CART cells, and probably also in the case of other CART cell approaches targeting 
kappa light chain39, CD13840, Lewis Y antigen41, BCMA42, CS143,44, and CD44v6.45 One 
future option to improve the target-specificity could be the optimization of the target cell 
affinity of CART cells. In addition, suicide genes may enable the in vivo control of adoptively 
transferred CART cells. Indeed, in our first attempt to improve the safety profile of CD38-
CART cells we observed, that the inducible caspase 9 (iCasp9) gene20,46 can effectively 
control CART cells. These results, which are in agreement with other studies20,45,47 provide 
positive prospects for the future clinical trials. The safety profile of CART cells could also be 
improved by the generation of inducible CAR constructs or using the recently developed 
dual CAR technologies.  
Taken together, we conclude that CD38-CART cells are powerful immunotherapeutic tools 
and can be beneficial especially for MM patients who have no other chemotherapy options. 
Therefore these results warrants further studies towards diminishing their undesired effects 
against normal CD38+ cells through optimizing their CD38 affinity and improving in vivo 
controllability. 
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Figure Legends 
 
Figure 1 CD38-CAR construct and CD38-CART cell phenotype 
(A) Schematic overview of the CD38-CAR construct. CD38-scFv sequence is based on 
three different antibody sequences (028, 056 and 26, see also supplementary Table S1), 
with CD8a as transmembrane domain and 4-1BB and CD3ζ as intracellular domains. (B) 
CAR expression on the cell surface of healthy donor T cells was determined by binding of 
biotinylated protein L to the scFv domain (left panel), stained with PE labeled streptavidin. 
Depicted are the results for CD38-CART cells generated with CAR056, representative for all 
three CARs. The expression of surface markers CD4 and CD8 on (right panel) was 
determined by fluorescence-labeled monoclonal antibodies. (C) The expansion of mock and 
CD38-CART cells after transduction (left panel) and after the second round of stimulation 
(right panel; new stimulation set at “0”). (D) The relative 3H-thymidine uptake (left panel) of 
mock and CD38-CART cells after 72 h stimulation with the CD38+ MM cell line UM9: 
responder ratio of 3:1. Error bars represent mean + SEM, n=3. The results are expressed 
as relative stimulation index, compared to mock and considered significant if the stimulation 
index is >=3. The cytokine secretion (right panel) from of mock and CD38-CART cells 
stimulated with αCD3/CD28 beads or CD38-specific with the MM cell line UM9. The 
cytokine secretion was measured with the flow cytometry-based CBA kit (BD) in the cell free 
supernatants after 24 hours of stimulation. Graph shows the secretion of IFN- γ, TNF and 
IL-2. Secretion of IL-4, -5 and -10 were below the detection limits. These data are therefore 
not shown in this figure. Similar results were obtained in two independent assays. 
Figure 2 Efficacy of CD38-CART cells to lyse MM cell lines. In 24 h cytotoxicity assays, 
three different CD38-CART cells were tested against two MM cell lines with different CD38 
expression levels (A) U266, a CD38-negative cell line, (B) UM9, a CD38+ cell line. 
Effector:Target ratios are indicated. Target cells per well were 10,000 MM cells. Closed 
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circles ( ) indicate mock and open squares, triangle and diamond (□, , ) indicate 
CAR028, 056 and 026. Error bars indicate mean + SD. (C) Correlation between mean 
fluorescent intensity (MFI) of CD38 on target cells and consequential CD38-CAR specific 
lysis. CD38-CART cells (CAR056) were co-cultured with leukemic cell lines and allogeneic 
healthy donor PBMCs. The resulting lysis in a 3:1 ratio was determined with BLI or flow 
cytometry, minus the spontaneous lysis caused by mock T cells. Open circles () indicate 
MM cell lines (LME-1, UM9, MM1.S, U266, L363 and UM3), triangles () indicate AML 
(HEL, MOLM13), T lymphoblast (CEM) and Burkitt Lymphoma (Daudi), closed circles ( ) 
indicate healthy immune cells (T= T cells, B=B cells, NK= NK cells, Mo= monocytes, 
C=CEM, H=HEL, M=MOLM13, D=Daudi), Error bars represent mean + SEM of duplicate 
measurements.. 
Figure 3. Efficacy of CD38-CART cells generated from healthy individuals to lyse 
primary MM cells. (A) Bone marrow derived mononuclear cells (BM-MNCs) of three MM 
patients, all three refractory to lenalidomide, and bortezomib and BM-MNCs of two AML 
patients were co-incubated with no, mock- or CD38-CART cells generated from healthy 
PBMC for 16 h. Closed circles ( ) indicate mock and open squares (□) indicate CAR056T 
cells (representative for all CARs). The graphs depict the resulting lysis of CD138+/CD38+ 
cells (MM) or CD13+/CD7+/CD45dim/CD38+ (AML1, moderate CD38 expression) and 
CD33+/CD133+/CD45dim/CD38+ (AML2, high CD38 expression) in three E:T ratios. The % 
lysis in these flow cytometry assays was calculated as described in the methods section. 
(B) Efficacy of CD38CART cells generated from a MM patient: CAR expression on the cell 
surface of patient’s T cells was determined by flow cytometry with protein L staining (see 
also figure 1). (C) Bone marrow derived mononuclear cells (BM-MNCs) of the MM patient 
were co-incubated with autologous mock- or CD38-CART cells for 16 h. The graph depicts 
resulting lysis of CD138+/CD38+ cells in two ratios, determined in flow cytometry based 
assays. .  
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Figure 4. Tumor growth in Mock- and CD38-CART cell treated mice. (A) Analysis of 
CD38-CART cells after two weeks of in vitro culture, with fluorescence labeled monoclonal 
antibodies for CD45RA and CD62L and CD38. (B) Leukocyte transmigration assay, where 
mock and CART cells were cultured in a transwell system in the inserts with endothelial 
(HUVEC) cells, which were activated with TNF-α. Spontaneous TNFα-induced 
transmigration was compared to active migration induced by 10% of human serum in the 
lower compartment. % migrated cells = (Relative Fluorescence Units (RFU) of cells in lower 
compartment / RFU of total cells in both compartments) * 100%. (C) Analysis of tumor load 
in mice by quantification of BLI measurements. Each group contained six mice, each 
harboring 6 scaffolds. Results are mean tumor load (cpm/cm2) of 6 mice per group. Closed 
circles ( ) indicate Mock and open squares (□) indicate CAR056. The error bars represent 
mean + SEM, n=6. The differences between groups were analyzed after week 6 in, an 
unpaired student’s T test, p < 0.0001 (D) Bioluminescent imaging of mice on right side, mice 
were implanted with fully humanized BMSC scaffolds each coated with 1×106 UM9-GFP-
Luc tumor cells. 7, 9 and 13 days after implantation, mice were i.v. injected with 20×106 
Mock or CD38-CART cells. (E) Representative immunohistochemistry figure, remaining 
tumor were stained with CD38 and CD138 antibody, T = tumor, sc = scaffold. 
 
Figure 5. The impact of CD38-CART cells on non-malignant hematopoietic cells in BM 
and outgrowth of Hematopoietic cell lineages. (A) BM-MNCs of 3 MM patients were co-
incubated with none, mock- or CD38-CART cells for 16 h. The graphs depict the resulting 
lysis of the total or the CD38+ fractions of CD3+ (T cells), CD56+, (mainly NK cells), CD14+ 
(monocytes) and CD19+ (B cells) cell subsets in three ratios, determined with flow cytometry 
and calculated as described in the methods section. Results are 3 individual experiments 
combined. Closed circles ( ) indicate Mock and open squares (□) indicate CAR056. Error 
bars represent mean + SEM, n=3. (B) CD34+ fraction of BM-MNCs from healthy donors 
were co-incubated with none, mock- or CD38-CART cells for 4 h at different T:BM cell ratios 
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before transferring into the semisolid HPC culture medium. After the incubation, cells were 
analyzed by flow cytometry for surviving CD34+ cells with CD38 expression. The graphs 
depict the resulting lysis of the total or the CD38+ fraction of CD34+ cells. Closed circles () 
indicate Mock and open squares (□) indicate CAR056. (C) After 14 days of culture in plastic 
dishes, colony-forming unit-monocytes (CFU-M), and CFU-granulocytes (CFU-G) were 
visible, (D) the number of CFU-M, and CFU-G colonies were determined microscopically. 
Results of a representative experiment are shown mean + SD.  
Figure 6. Dimerizer AP20187-mediated elimination of the iCasp9 suicide gene 
transduced CD38-CAR T cells. (A) Flow cytometry histogram plots, CD38-CAR T cells 
that were additionally transduced with the iCasp9-GFP construct. Upper panel shows the 
untreated cells 50% GFP+; lower panel the cells treated with 100nM dimerizer AP20187 
(B/B). (B) The lysis of UM9 cell line by iCasp9-transduced CD38-CAR T cells that were 
untreated or treated with the dimerizer. The significant reduction of GFP+ cells (A) is a 
consequence of cell death activated by the dimerizer B/B. Note (in B) the decrease in 
cytolysis is proportional to the elimination of the suicide gen transduced cells (50% of all 
CAR-positive cells in A. The residual cytolysis is thus caused by the CAR-positive cells that 
were not transduced with iCasp9 n=2, mean + SD. (C) CD38-CART iCasp9-GFP-high 
sorted cells. Upper panel shows the untreated cells 100% GFP+; lower panel the cells 
treated with 100nM dimerizer B/B. (D) The lysis of UM9 cell line by iCasp9-High-CD38-
CART cells that were untreated or treated with the dimerizer. Closed circles () indicate 
Mock and open diamond ( ) and triangle ( ) indicate CAR056 – and + B/B. n=2, mean + 
SD. 
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